158 related articles for article (PubMed ID: 28470127)
1. Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis.
Ovejero-Benito MC; Prieto-Pérez R; Llamas-Velasco M; Belmonte C; Cabaleiro T; Román M; Ochoa D; Talegón M; Saiz-Rodríguez M; Daudén E; Abad-Santos F
Pharmacogenomics; 2017 May; 18(7):631-638. PubMed ID: 28470127
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis.
Ovejero-Benito MC; Prieto-Pérez R; Llamas-Velasco M; Muñoz-Aceituno E; Reolid A; Saiz-Rodríguez M; Belmonte C; Román M; Ochoa D; Talegón M; Cabaleiro T; Daudén E; Abad-Santos F
Pharmacogenomics; 2018 Jan; 19(1):7-16. PubMed ID: 29192552
[TBL] [Abstract][Full Text] [Related]
3. New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis.
Prieto-Pérez R; Solano-López G; Cabaleiro T; Román M; Ochoa D; Talegón M; Baniandrés O; López-Estebaranz JL; de la Cueva P; Daudén E; Abad-Santos F
Pharmacogenomics J; 2018 Jan; 18(1):70-75. PubMed ID: 27670765
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study.
Xie F; Wang R; Zhao ZG; Meng XF; Lin BW; Yang J; Wang WJ; Ding XY; Yang Y; Zhao H; Li CX; Li HJ; Zhou Y
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):943-947. PubMed ID: 29270758
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.
Prieto-Pérez R; Llamas-Velasco M; Cabaleiro T; Solano-López G; Márquez B; Román M; Ochoa D; Talegón M; Daudén E; Abad-Santos F
Pharmacogenomics; 2017 Jan; 18(2):157-164. PubMed ID: 27977334
[TBL] [Abstract][Full Text] [Related]
6. Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis.
Murdaca G; Negrini S; Magnani O; Penza E; Pellecchio M; Puppo F
Expert Opin Drug Saf; 2017 Oct; 16(10):1173-1179. PubMed ID: 28750567
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study.
Di Lernia V; Guarneri C; Stingeni L; Gisondi P; Bonamonte D; Calzavara Pinton PG; Offidani A; Hansel K; Girolomoni G; Filoni A; Belloni Fortina A; Ficarelli E; Cannavò SP
J Dermatolog Treat; 2018 May; 29(3):217-219. PubMed ID: 28783991
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Efficacy of Etanercept for Plaque-Type Psoriasis and Estimated Cost in Daily Clinical Practice.
María Fernández-Torres R; Paradela S; Fonseca E
Value Health; 2015 Dec; 18(8):1158-61. PubMed ID: 26686803
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of clinical use of etanercept for the treatment of moderate-to-severe psoriasis in Spain: results of a multicentric prospective study at 12 months follow-up.
Puig L; Camacho Martínez FM; Gimeno Carpio E; López-Ávila A; García-Calvo C
Dermatology; 2012; 225(3):220-30. PubMed ID: 23235195
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of etanercept combined plus methotrexate and comparison of expression of pro-inflammatory factors expression for the treatment of moderate-to-severe plaque psoriasis.
Yu Q; Tong Y; Cui L; Zhang L; Gong Y; Diao H; Gao F; Shi Y
Int Immunopharmacol; 2019 Aug; 73():442-450. PubMed ID: 31154289
[TBL] [Abstract][Full Text] [Related]
11. HLA-Cw6 allele, NFkB1 and NFkBIA polymorphisms play no role in predicting response to etanercept in psoriatic patients.
Caldarola G; Sgambato A; Fanali C; Moretta G; Farina M; Lucchetti D; Peris K; De Simone C
Pharmacogenet Genomics; 2016 Sep; 26(9):423-7. PubMed ID: 27348478
[TBL] [Abstract][Full Text] [Related]
12. Long-term (1 year) efficacy of etanercept in moderate-to-severe psoriasis. Results of a multicentric observational study in Spain.
Puig L; Camacho F; García-Patos V; Fernández-Díaz ML; Marquina A; García-Calvo C
Eur J Dermatol; 2015; 25(5):410-7. PubMed ID: 26080687
[TBL] [Abstract][Full Text] [Related]
13. Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value.
Elberdín L; Outeda M; Salvador P; Paradela S; Fernández-Torres RM; Iglesias R; Fonseca E; Martín I
Int J Clin Pharm; 2016 Oct; 38(5):1142-8. PubMed ID: 27436193
[TBL] [Abstract][Full Text] [Related]
14. Measurement of circulating miRNA-125a exhibits good value in the management of etanercept-treated psoriatic patients.
Pei D; Cao J; Qin G; Wang X
J Dermatol; 2020 Feb; 47(2):140-146. PubMed ID: 31820498
[TBL] [Abstract][Full Text] [Related]
15. The association between etanercept serum concentration and psoriasis severity is highly age-dependent.
Detrez I; Van Steen K; Segaert S; Gils A
Clin Sci (Lond); 2017 Jun; 131(11):1179-1189. PubMed ID: 28420676
[TBL] [Abstract][Full Text] [Related]
16. Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study.
Mrowietz U; Chouela EN; Mallbris L; Stefanidis D; Marino V; Pedersen R; Boggs RL
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1114-20. PubMed ID: 25376448
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation.
Campanati A; Goteri G; Simonetti O; Ganzetti G; Giuliodori K; Giuliano A; Sabato S; Stramazzotti D; Gulini E; Dusi D; De Blasio S; Fabris G; Offidani A
Int J Immunopathol Pharmacol; 2009; 22(2):371-7. PubMed ID: 19505391
[TBL] [Abstract][Full Text] [Related]
18. An observational study to evaluate the long-term outcomes of treatment with etanercept in patients with plaque-type psoriasis.
Luger T; Schopf RE; Schwanke A; Langhammer S; Meng T; Löschmann PA
J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):1730-1741. PubMed ID: 27297981
[TBL] [Abstract][Full Text] [Related]
19. A preliminary prospective non-randomized controlled trial to compare the efficacy of subcutaneous etanercept versus oral methotrexate in moderate-to-severe chronic plaque psoriasis and correlation of response with T helper (th) 1, th2, th17 and T regulatory cytokine patterns.
Khandpur S; Singh A; Kumar A; Sharma A
Indian J Dermatol Venereol Leprol; 2020; 86(4):441-445. PubMed ID: 32496226
[No Abstract] [Full Text] [Related]
20. Clinical experience with the etanercept biosimilar SB4 in psoriatic patients.
Pescitelli L; Lazzeri L; Di Cesare A; Tripo L; Ricceri F; Prignano F
Int J Clin Pharm; 2019 Feb; 41(1):9-12. PubMed ID: 30610544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
